BR112013031570A2 - inalador de pó seco. - Google Patents

inalador de pó seco.

Info

Publication number
BR112013031570A2
BR112013031570A2 BR112013031570A BR112013031570A BR112013031570A2 BR 112013031570 A2 BR112013031570 A2 BR 112013031570A2 BR 112013031570 A BR112013031570 A BR 112013031570A BR 112013031570 A BR112013031570 A BR 112013031570A BR 112013031570 A2 BR112013031570 A2 BR 112013031570A2
Authority
BR
Brazil
Prior art keywords
dry powder
powder inhaler
inhaler
dry
powder
Prior art date
Application number
BR112013031570A
Other languages
English (en)
Inventor
Crater Glenn
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of BR112013031570A2 publication Critical patent/BR112013031570A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • A61M15/0028Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/0045Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
BR112013031570A 2011-06-08 2012-06-01 inalador de pó seco. BR112013031570A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161494594P 2011-06-08 2011-06-08
PCT/EP2012/060442 WO2012168160A1 (en) 2011-06-08 2012-06-01 Dry powder inhaler compositions comprising umeclidinium

Publications (1)

Publication Number Publication Date
BR112013031570A2 true BR112013031570A2 (pt) 2017-03-21

Family

ID=46201673

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013031570A BR112013031570A2 (pt) 2011-06-08 2012-06-01 inalador de pó seco.

Country Status (10)

Country Link
US (1) US20140116434A1 (pt)
EP (1) EP2717867A1 (pt)
JP (1) JP2014518894A (pt)
KR (1) KR20140041700A (pt)
CN (1) CN103561731A (pt)
AU (1) AU2012266540A1 (pt)
BR (1) BR112013031570A2 (pt)
CA (1) CA2838031A1 (pt)
RU (1) RU2013153202A (pt)
WO (1) WO2012168160A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2400950B1 (en) 2009-02-26 2019-05-22 Glaxo Group Limited Pharmaceutical formulations comprising 4-{(1 r)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
RU2666963C2 (ru) 2012-04-13 2018-09-13 Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Агрегированные частицы
GB201222679D0 (en) 2012-12-17 2013-01-30 Glaxo Group Ltd Pharmaceutical combination products
AU2015275933A1 (en) 2014-06-18 2017-02-02 Cipla Limited Pharmaceutical composition comprising a beta-2-agonist and anticholinergic agent
CN105461710A (zh) * 2015-10-23 2016-04-06 安徽德信佳生物医药有限公司 一种芜地溴铵的制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
AU2001275760B2 (en) 2000-08-05 2005-03-17 Glaxo Group Limited 6.alpha., 9.alpha.-difluoro-17.alpha.-'(2-furanylcarboxyl) oxy!-11.beta.-hydroxy-16.alpha.-methyl-3-oxo-androst-1,4,-diene-17-carbothioic acid S-fluoromethyl ester as an anti-inflammatory agent
ATE417606T1 (de) 2001-09-14 2009-01-15 Glaxo Group Ltd Phenethanolamin-derivate zur behandlung von erkrankungen der atemwege
GB0201677D0 (en) 2002-01-25 2002-03-13 Glaxo Group Ltd Medicament dispenser
GB0217196D0 (en) * 2002-07-25 2002-09-04 Glaxo Group Ltd Medicament dispenser
JP2007528414A (ja) * 2004-03-11 2007-10-11 セラヴァンス, インコーポレーテッド ムスカリンレセプターアンタゴニストとしての有用なジフェニルメチル化合物
AR050902A1 (es) 2004-04-27 2006-12-06 Glaxo Group Ltd Compuesto de quinuclidina, composicion farmaceutica que lo comprende y su usopara preparar dicha composicion
GB0515584D0 (en) 2005-07-28 2005-09-07 Glaxo Group Ltd Medicament dispenser
AR058289A1 (es) 2005-12-12 2008-01-30 Glaxo Group Ltd Colector para ser usado en dispensador de medicamento
AU2010258751A1 (en) * 2009-06-09 2012-02-02 Sunovion Respiratory Development Inc. Treatment of chronic obstructive pulmonary disease with nebulized beta 2-agonist or combined nebulized beta 2-agonist and anticholinergic administration
GB0921075D0 (en) * 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents

Also Published As

Publication number Publication date
JP2014518894A (ja) 2014-08-07
AU2012266540A1 (en) 2014-01-09
KR20140041700A (ko) 2014-04-04
RU2013153202A (ru) 2015-07-20
CA2838031A1 (en) 2012-12-13
EP2717867A1 (en) 2014-04-16
WO2012168160A1 (en) 2012-12-13
CN103561731A (zh) 2014-02-05
US20140116434A1 (en) 2014-05-01

Similar Documents

Publication Publication Date Title
BR112014004921A2 (pt) dispositivo inalador de pó seco
BR112016011996A2 (pt) inalador de pó seco
HK1204989A1 (en) Inhalable dry powders
BR112013014958A2 (pt) inalador de pó seco
BR112015004233A2 (pt) inalador.
CO6801645A2 (es) Nuevos inmunoconjugados
FR2962343B1 (fr) Inhalateur de poudre seche.
FR2987609B1 (fr) Moyens antiaffaissement
BR112014029111A2 (pt) inalador
BR112015004230A2 (pt) inalador.
FR2962338B1 (fr) Inhalateur de poudre seche.
BR112013031572A2 (pt) produto de combinação farmacêutica, e, inalador de pó seco.
FR2962342B1 (fr) Inhalateur de poudre seche.
FR2962337B1 (fr) Inhalateur de poudre seche.
BR112013031570A2 (pt) inalador de pó seco.
DE102012213479B8 (de) Positionsdetektor
FR2986872B1 (fr) .
FR2977498B1 (fr) Inhalateur de poudre seche.
CL2015001192A1 (es) Composición herbicida
FR2962339B1 (fr) Inhalateur de poudre seche.
BR112013032873A2 (pt) arranjo de distribuição rotativo
BR112014001001A2 (pt) pó de polímero
FR2978994B1 (fr) .
DK2500470T3 (da) Hoved-arbejdsvogn
FR2999560B1 (fr) Poudre de cristallites

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]